Bristol-Myers licenses a second-line HIV drug for cheap copies in poor nations

Bristol-Myers Squibb ($BMY) agreed to license its HIV fighter Reyataz (atazanavir) to the Medicines Patent Pool, which will allow generics makers to turn out cheaper copies for sale in poor countries. Reyataz is designed for patients who've failed on previous drugs, and it's the first such second-line treatment in the pool. Release | Report